Advances in the development of genetic markers for the diagnosis of disease and drug response

Expert Review of Molecular Diagnostics

Volumn 2, Issue 5, 2002, Pages 411-421

  Halapi, Eva ^a   Hakonarson, Hakon ^a  

^a DECODE GENETICS   (Iceland)

Author keywords

Drug response; Genetic diagnosis; Genetic marker; Pharmacogenomics

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; ACYLTRANSFERASE; APOLIPOPROTEIN E; AZATHIOPRINE; BCR ABL PROTEIN; BETA 2 ADRENERGIC RECEPTOR; CYTOCHROME P450; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; DIPEPTIDYL CARBOXYPEPTIDASE; DOPAMINE 3 RECEPTOR; HISTAMINE H1 RECEPTOR; IMATINIB; IMMUNOGLOBULIN E; KI 67 ANTIGEN; LEUKOTRIENE C4; LEUKOTRIENE C4 SYNTHASE; LEUKOTRIENE D4; LEUKOTRIENE E4; MERCAPTOPURINE; PROTEIN P53; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR; SEROTONIN 5A RECEPTOR; SEROTONIN TRANSPORTER; STEM CELL FACTOR; THIOPURINE METHYLTRANSFERASE; TIOGUANINE; TRASTUZUMAB; UNINDEXED DRUG;

ASTHMA; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; ENZYME POLYMORPHISM; GENETIC MARKER; GENETIC VARIABILITY; HUMAN; LEUKEMIA; PHARMACOGENOMICS; REVIEW; THERAPY RESISTANCE;

EID: 0036713298     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737159.2.5.411     Document Type: Review

References (110)

1. Principles in pharmacogenetics
2. Association between β2-adrenoceptor polymorphism and susceptibility to bronchodilator desensitisation in moderately severe stable asthmatics
3. Pharmacogenetics and the practice of medicine
4. Pharmacogenomics: Unlocking the human genome for better drug therapy
5. How the pharmacogenetics of cytochrome P450 enzymes may affect prescribing
6. Pharmacogenetics and pharmacogenomics: Tailored drug therapy for the 21st century
7. Drug target validation and identification of secondary drug target effects using DNA microarrays
8. Potassium ion channels and human disease: Phenotypes and drug targets?
9. Pharmacogenetics and future drug development and delivery
10. Association of polymorphisms in the cytochrome 450 CYP2C9 with warfarin dose requirement and risk of bleeding complications
11. High risk for hyperlipidemia and the metabolic syndrome after an episode of hypertriglyceridemia during 13-cis retinoic acid therapy for acne: A pharmacogenetic study
12. Drug therapy in the old age. Drug effects in the elderly
13. Approaches to breast-cancer staging
14. Cytokeratin-positive cells in the bone marrow and survival of patients with Stage I, II, or III breast cancer
15. Staging of non-small-cell lung cancer with positron-emission tomography
16. Cell cycle control as a basis for cancer drug development
17. Molecular alterations in bladder cancer
18. Tissue plasminogen activator is required for the growth, invasion and angiogenesis of pancreatic tumor cells
19. Recent advances in research on multistage tumorigenesis
20. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
21. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
22. Amplification and overexpression of the erbB-2 gene in human tumors: Its involvement in tumor development, significance as a prognostic factor and potential as a target for cancer therapy
23. The biology of erbB-2/neu/HER-2 and its role in cancer
24. The HER-2/neu oncogene in breast cancer: Prognostic factor, predictive factor and target for therapy
25. HER-2/neu amplification predicts poor survival in node positive patients
26. c-erbB-2 overexpression in amplified and non-amplified breast carcinoma samples
27. Update of recommendations for the use of tumor markers in breast and colorectal cancer: Clinical practice guidelines of the American Society of Clinical Oncology
28. Imatinib mesylate - A new oral targeted therapy, 2002
29. Smart drugs: Tyrosine kinase inhibitors in cancer therapy
30. Fused transcript of abl and bcr genes in chronic myelogenous leukaemia
31. Prognostic factors in node-negative breast cancer: A review of studies with sample size more than 200 and follow-up more than 5 years
32. New molecular tools for efficient screening of cervical cancer
33. Genetic polymorphism of thiopurine S-methyltransferase: Clinical importance and molecular mechanisms
34. Concordance of phenotype and genotype for CYP2D6
35. The thiopurine S-methyltransferase gene locus implications for clinical pharmacogenomics
36. Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia
37. Genetic variations in the acetylation of isoniazid and other drugs
38. Arylamine N-acetyltransferases
39. Role of N-acetyltransferase phenotypes in bladder carcinogenesis: A pharmacogenetic epidemiological approach to bladder cancer
40. Genetic polymorphisms in human drug-metabolizing enzymes: Potential uses of reverse genetics to identify genes of toxicological relevance
41. Arylamine N-acetyltransferases of mice, men and microorganisms
42. Prevention of cardiovascular events and death with pravastatine in patients with coronary heart disease and a broad range of initial cholesterol levels
43. The effect of pravastatine on coronary events after myocardial infarction in patients with average cholesterol levels
44. Primary prevention of acute coronary events with lovastatine in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS
45. Prevention of coronary heart disease with pravastatine in men with hypercholesterolemia
46. Genes, variation of cholesterol and fat intake and serum lipids
47. Apolipoprotein E polymorphism and atherosclerosis
48. Human apolipoprotein E isoprotein subclasses are genetically determined
49. Effect of apolipoprotein E and A-IV phenotypes on the low density lipoprotein response to HMG CoA reductase inhibitor therapy
50. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis
51. 455G/A polymorphism of the β-fibrinogen gene is associated with the progression of coronary atherosclerosis in symptomatic men: Proposed role for an acute-phase reaction pattern of fibrinogen
52. The Asp9 Asn mutation in the lipoprotein lipase gene is associated with increased progression of coronary atherosclerosis. REGRESS Study Group, Interuniversity Cardiology Institute, Utrecht, The Netherlands. Regression Growth Evaluation Statin study
53. Common hepatic lipase gene promoter variant determines clinical response to intensive lipid-lowering treatment
54. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels
55. Quinapril prevents restenosis after coronary stenting in patients with angiotensin-converting enzyme D allele
56. D allele of the angiotensin I-converting enzyme is a major risk factor for restenosis after coronary stenting
57. Effect of the stromelysin-1 promoter on efficacy of pravastatin in coronary atherosclerosis and restenosis
58. Pharmacogenetics of asthma
59. The pharmacogenetics of β2-adrenergic receptors: Relevance to asthma
60. Mutations in the gene encoding for the β2-adrenergic receptor in normal and asthmatic subjects
61. β2-adrenoceptor polymorphisms are in linkage disequilibrium but are not associated with asthma in an adult population
62. The glutamine 27 β 2 adrenoceptor polymorphism is associated with elevated immunoglobulin E levels in asthmatic families
63. Regulation of IgE production from human mononudear cells by 2-adrenoceptor agonists
64. Association between genetic polymorphisms of the β2-adrenoceptor and response to albuterol in children with and without a history of wheezing
65. Association of persistent bronchial hyperresponsiveness with 2-adrenoceptor (ADRB2) haplotypes
66. Polymorphism of the 2-adrenoceptor and the response to long-term 2-agonist therapy in asthma
67. Leukotrienes and lipoxins: Structures, biosynthesis and biological effects
68. Treatment of asthma with drugs modifying the leukotriene pathway
69. Naturally occurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription
70. Egr-1 and Sp1 interact functionally with the 5-lipoxygenase promoter and its naturally occurring mutants
71. Leukotriene C-4 synthase: A pivotal enzyme in the biosynthesis of the cysteinyl leukotrienes
72. Variant LTC4 synthase allele modifies cysteinyl leukotriene synthesis in eosinophils and predicts clinical response to zafirlukast
73. Glucocorticoid receptor, a potential endogenous inhibitor of glucocorticoid action in humans
74. Pathogenesis of steroid-resistant asthma
75. Glucocorticoid resistance in asthma is associated with elevated in vivo expression of the glucocorticoid receptor-isoform
76. Steroid-resistant asthma: Cellular mechanisms contributing to inadequate responses to glucocorticoid therapy
77. Steroid resistant asthma: What is the clinical definition?
78. Pharmacogenomics study predicts glucocorticoid responsivness with high accuracy
79. A major susceptibility gene for asthma maps to chromosome 14q24
80. Progress and pitfalls: Bipolar molecular linkage studies
81. Differentiation of two genetically specific types of depression by the response to antidepressant drugs
82. Physiological genomics of antidepressant targets: Keeping the periphery in mind
83. Pharmacogenetics in affective disorders
84. Pharmacokinetics of selective serotonin re-uptake inhibitors
85. Allelic variation of human serotonin transporter gene expression
86. The human serotonin transporter gene polymorphism-basic research and clinical implications
87. Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine
88. Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of serotonin transporter gene
89. Dopamine D3 receptor gene polymorphism and response to dozapine in schizophrenic Pakastani patients
90. Allelic association between a Ser-9-Gly polymorphism in the dopamine D3 receptor gene and schizophrenia
91. The dopamine D3 receptor (DRD3) Ser9Gly polymorphism and schizophrenia: A haplotype relative risk study and association with dozapine response
92. Polymorphisms of the dopamine D4 receptor and response to antipsychotic drugs
93. Dopamine D4 receptor gene polymorphisms and neuroleptic response in schizophrenia
94. Association between dozapine response and allelic variation in 5-HT2A receptor gene
95. Evidence for association between polymorphisms in the promoter and coding regions of the 5-HT2A receptor gene and response to dozapine
96. Association analysis of the 5-HT5A gene in depression, psychosis and antipsychotic response
97. Pharmacogenetic prediction of dozapine response
98. Lack of association between the T->C 267 serotonin 5-HT6 receptor gene (HTR6) polymorphism and prediction of response to clozapine in schizophrenia
99. Apolipoprotein E: A pharmacogenetic target for the treatment of Alzheimer's disease
100. Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer's disease
101. APOE genotyping and response to drug treatment in Alzheimer's disease
102. Human drug metabolism and the cytochromes P450: Application and relevance of in vitro models
103. Human cytochromes P450
104. Internal duplication and homology with bacterial transport proteins in the mdR1 (P-glycoprotein) gene from multi-drug resistant human cells
105. Pharmacogenetics of the human drug-transporter gene MDR1: Impact of polymorphisms on pharmacotherapy
106. P-glycoprotein is an independent prognostic factor predicting relapse in childhood acute lymphoblastic leukaemia: Results of a 6-year prospective study
107. Functional polymorphisms of the human multi-drug resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo
108. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multi-drug resistance transporter 1: A pharmacogenetics study
109. Multi-drug resistance-1 (MDR-1) in rheumatic autoimmune disorders. Part II: Increased P-glycoprotein activity in lymphocytes from systemic lupus erythematosus patients might affect steroid requirements for disease control
110. High multi-drug resistance (P-glycoprotein 170) expression in inflammatory bowel disease patients who fail medical therapy